Literature DB >> 27173747

Off the shelf cellular therapeutics: Factors to consider during cryopreservation and storage of human cells for clinical use.

Erik J Woods1, Sreedhar Thirumala2, Sandhya S Badhe-Buchanan3, Dominic Clarke4, Aby J Mathew5.   

Abstract

The field of cellular therapeutics has immense potential, affording an exciting array of applications in unmet medical needs. One of several key issues is an emphasis on getting these therapies from bench to bedside without compromising safety and efficacy. The successful commercialization of cellular therapeutics will require many to extend the shelf-life of these therapies beyond shipping "fresh" at ambient or chilled temperatures for "just in time" infusion. Cryopreservation is an attractive option and offers potential advantages, such as storing and retaining patient samples in case of a relapse, banking large quantities of allogeneic cells for broader distribution and use and retaining testing samples for leukocyte antigen typing and matching. However, cryopreservation is only useful if cells can be reanimated to physiological life with negligible loss of viability and functionality. Also critical is the logistics of storing, processing and transporting cells in clinically appropriate packaging systems and storage devices consistent with quality and regulatory standards. Rationalized approaches to develop commercial-scale cell therapies require an efficient cryopreservation system that provides the ability to inventory standardized products with maximized shelf life for later on-demand distribution and use, as well as a method that is scientifically sound and optimized for the cell of interest. The objective of this review is to bridge this gap between the basic science of cryobiology and its application in this context by identifying several key aspects of cryopreservation science in a format that may be easily integrated into mainstream cell therapy manufacture.
Copyright © 2016 International Society for Cellular Therapy. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  cell manufacturing; cellular shelf life; cellular stability; cellular therapeutics; cryopreservation; stem cell therapy

Mesh:

Substances:

Year:  2016        PMID: 27173747     DOI: 10.1016/j.jcyt.2016.03.295

Source DB:  PubMed          Journal:  Cytotherapy        ISSN: 1465-3249            Impact factor:   5.414


  26 in total

1.  Effect of Cryopreservation on Autologous Chimeric Antigen Receptor T Cell Characteristics.

Authors:  Sandhya R Panch; Sandeep K Srivastava; Nasha Elavia; Andrew McManus; Shutong Liu; Ping Jin; Steven L Highfill; Xiaobai Li; Pradeep Dagur; James N Kochenderfer; Terry J Fry; Crystal L Mackall; Daniel Lee; Nirali N Shah; David F Stroncek
Journal:  Mol Ther       Date:  2019-05-30       Impact factor: 11.454

2.  Long-Term Cryopreservation and Revival of Tissue-Engineered Skeletal Muscle.

Authors:  Lauren Grant; Ritu Raman; Caroline Cvetkovic; Meghan C Ferrall-Fairbanks; Gelson J Pagan-Diaz; Pierce Hadley; Eunkyung Ko; Manu O Platt; Rashid Bashir
Journal:  Tissue Eng Part A       Date:  2019-01-09       Impact factor: 3.845

3.  Optimisation of a potency assay for the assessment of immunomodulative potential of clinical grade multipotent mesenchymal stromal cells.

Authors:  Irene Oliver-Vila; Carmen Ramírez-Moncayo; Marta Grau-Vorster; Sílvia Marín-Gallén; Marta Caminal; Joaquim Vives
Journal:  Cytotechnology       Date:  2018-01-10       Impact factor: 2.058

4.  Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity.

Authors:  Huang Zhu; Robert H Blum; Ryan Bjordahl; Svetlana Gaidarova; Paul Rogers; Tom Tong Lee; Ramzey Abujarour; Gregory B Bonello; Jianming Wu; Pei-Fang Tsai; Jeffrey S Miller; Bruce Walcheck; Bahram Valamehr; Dan S Kaufman
Journal:  Blood       Date:  2020-02-06       Impact factor: 22.113

5.  Response by Luo et al to Letter Regarding Article, "Fabrication of Synthetic Mesenchymal Stem Cells for the Treatment of Acute Myocardial Infarction in Mice".

Authors:  Lan Luo; Tao-Sheng Li; Junnan Tang; Ke Cheng
Journal:  Circ Res       Date:  2017-05-26       Impact factor: 17.367

6.  Comparison of freshly cultured versus cryopreserved mesenchymal stem cells in animal models of inflammation: A pre-clinical systematic review.

Authors:  Chintan Dave; Shirley H J Mei; Andrea McRae; Christine Hum; Katrina J Sullivan; Josee Champagne; Tim Ramsay; Lauralyn McIntyre
Journal:  Elife       Date:  2022-07-15       Impact factor: 8.713

Review 7.  Manufacturing of primed mesenchymal stromal cells for therapy.

Authors:  James Q Yin; Jun Zhu; James A Ankrum
Journal:  Nat Biomed Eng       Date:  2019-01-28       Impact factor: 25.671

8.  Cryopreservation timing is a critical process parameter in a thymic regulatory T-cell therapy manufacturing protocol.

Authors:  Katherine N MacDonald; Sabine Ivison; Keli L Hippen; Romy E Hoeppli; Michael Hall; Grace Zheng; I Esme Dijke; Mohammed Al Aklabi; Darren H Freed; Ivan Rebeyka; Sanjiv Gandhi; Lori J West; James M Piret; Bruce R Blazar; Megan K Levings
Journal:  Cytotherapy       Date:  2019-12-03       Impact factor: 5.414

9.  Cryopreserved clumps of mesenchymal stem cell/extracellular matrix complexes retain osteogenic capacity and induce bone regeneration.

Authors:  Souta Motoike; Mikihito Kajiya; Nao Komatsu; Manabu Takewaki; Susumu Horikoshi; Shinji Matsuda; Kazuhisa Ouhara; Tomoyuki Iwata; Katsuhiro Takeda; Tsuyoshi Fujita; Hidemi Kurihara
Journal:  Stem Cell Res Ther       Date:  2018-03-21       Impact factor: 6.832

10.  Development, functional characterization and validation of methodology for GMP-compliant manufacture of phagocytic macrophages: A novel cellular therapeutic for liver cirrhosis.

Authors:  Alasdair R Fraser; Chloe Pass; Paul Burgoyne; Anne Atkinson; Laura Bailey; Audrey Laurie; Neil W A McGowan; Akib Hamid; Joanna K Moore; Benjamin J Dwyer; Marc L Turner; Stuart J Forbes; John D M Campbell
Journal:  Cytotherapy       Date:  2017-06-30       Impact factor: 5.414

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.